NASDAQ:SPRO • US84833T1034
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SPERO THERAPEUTICS INC (SPRO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-01-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-20 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-12-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-11-15 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-11-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-06 | TD Cowen | Upgrade | Hold -> Buy |
| 2024-08-06 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-04 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-26 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-23 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-20 | Berenberg | Downgrade | Buy -> Hold |
| 2022-05-17 | Cantor Fitzgerald | Maintains | Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 53.51M 193.04% | 103.781M 93.95% | 47.977M -53.77% | 26.01M -45.79% | 816K -96.86% | 3.264M 300.00% | 33.762M 934.38% | 101.08M 199.39% | 126.38M 25.03% | 185.44M 46.73% | 208.28M 12.32% | |
| EBITDA YoY % growth | -29.7M 65.99% | 27.154M 191.43% | -72.482M -366.93% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -30.57M 65.25% | 26.787M 187.63% | -72.484M -370.59% | -37.128M 48.78% | -38.046M -2.47% | -42.432M -11.53% | -8.16M 80.77% | 51.816M 735.00% | 80.988M 56.30% | 131.17M 61.96% | 181.05M 38.03% | |
| Operating Margin | -57.13% | 25.81% | -151.08% | -142.75% | -4,662.50% | -1,300.00% | -24.17% | 51.26% | 64.08% | 70.73% | 86.93% | |
| EPS YoY % growth | -1.66 42.56% | 0.52 131.33% | -1.27 -344.23% | -0.10 109.45% | 0.68 469.50% | -0.69 -201.49% | -1.13 -63.24% | 0.65 157.66% | 0.02 -96.88% | -0.82 -4,100.00% | 2.42 396.25% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.18 26.56% | -0.17 -478.00% | -0.16 -25.54% | -0.17 -132.72% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
6 analysts have analysed SPRO and the average price target is 4.08 USD. This implies a price increase of 67.9% is expected in the next year compared to the current price of 2.43.
SPERO THERAPEUTICS INC (SPRO) will report earnings on 2026-05-11.
The number of analysts covering SPERO THERAPEUTICS INC (SPRO) is 6.